Companies › NEC OncoImmunity
1 active drug program in 1 registered trial: 1 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NECVAX-NEO1 Personalized neoantigen-based T-cell vaccine using oral Ty21a vector with eukaryotic expre | – | Phase 1 | Solid Tumors, Adult | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05354323 | NECVAX-NEO1 | Phase 1 | Solid Tumors, Adult | Oncology | Dec 2025 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.